HSBC Downgrades Lilly Stock Ahead of Expected Weight Loss Drug Price Cuts
HSBC has downgraded Eli Lilly (Lilly) stock, anticipating deeper price cuts for its weight loss drugs. This decision reflects concerns about the potential impact on Lilly's revenue and profitability.